VERTX Pharma is engaged in advanced chemical synthesis, custom research, and manufacturing services to support the pharmaceutical industry's material and service needs.
We specialize in a wide range of synthetic transformations including Hydrogenation, Acylation, Aldol Condensation, Chlorination, Nitration, Birch Reduction, Diazotisation, and Carbonylation. We also have expertise in handling sensitive reagents such as n-Butyllithium, Palladium on Carbon, Raney Nickel, Sodium Hydride, LAH, NaH, L-Selectride, and Sodium Borohydride.
Expertise in asymmetric synthesis and chiral resolution techniques for enantiomerically pure compounds.
Specialized handling of air-sensitive and moisture-sensitive chemistry under inert atmosphere conditions.
Proficient in transition metal catalysis and organometallic transformations for complex synthesis.
Advanced reduction techniques including catalytic hydrogenation and selective reducing agents.
Expert handling of Grignard reagents and related organometallic coupling reactions.
Complex multi-step synthetic routes designed and optimized for efficiency and yield.
Seamless scale-up from milligram to multi-kilogram quantities with process optimization.
Safe handling of high-reactivity chemicals
Well-established R&D facility undertaking short-term and long-term contracts for medicinal chemistry research. We custom synthesize exclusive products and libraries for clients, providing FTE/FEE services with complete project management. Equipped for optimization and validation from gram to kilogram, preparing kilogram batches for technology transfer to pilot plant and bulk manufacturing.
We sign MOU and CDA for exclusive partnerships to develop and manufacture small-scale and large-scale intermediates. Large-scale production is conducted at third-party manufacturing plants under our expert supervision, ensuring quality and compliance at every stage.
VertX Research develops processes for new or existing API intermediates in milligram to gram quantities, scaling up for pilot plant production and commercial manufacturing in tons. Full technology transfer support from lab to commercial scale.
Comprehensive offerings for pharmaceutical development
Comprehensive impurity catalog for pharmaceutical quality control
| Drug / Compound | Impurity Name | Source |
|---|---|---|
| Abiraterone | DHPG Oxime acetate of Abiraterone | In-house |
| DHPG acetate of Abiraterone | In-house | |
| Hydrazine Impurity of Abiraterone | In-house | |
| Hydroxylamine Impurity of Abiraterone | In-house | |
| Isopropyl Bromide Impurity of Abiraterone | In-house | |
| Aciclovir | Aciclovir Impurity A | EP |
| Aciclovir Impurity B | EP | |
| Aciclovir Impurity C | EP | |
| Aciclovir Impurity D | EP | |
| Aciclovir Impurity E | EP | |
| Aciclovir Impurity F | EP | |
| Aciclovir Impurity G | EP | |
| Aciclovir Impurity H | EP | |
| Albendazole | Albendazole Impurity A | EP |
| Albendazole Impurity B | EP | |
| Albendazole Impurity C | EP | |
| Albendazole Impurity D | EP | |
| Albendazole Impurity E | EP | |
| Albendazole Impurity F | EP | |
| Albendazole Impurity G (Chlorocarbendazole) | EP | |
| Allopurinol | Allopurinol Impurity A | EP |
| Allopurinol Impurity F | EP | |
| Ambrisentan | Ambrisentan Epoxy Impurity | In-house |
| Ambrisentan Impurity-1 (2,3-dihydroxy-3,3-Biphenyl propionic acid methyl ester) | In-house | |
| Ambroxol | Ambroxol Impurity A | EP |
| Ambroxol Impurity B | EP | |
| Ambroxol Impurity C | EP | |
| Ambroxol Impurity D | EP | |
| Ambroxol Impurity E | EP | |
| Amikacin | Amikacin Impurity B | EP |
| Amikacin Impurity F | EP | |
| Amlodipine | Amlodipine Related Compound A | USP |
| Amlodipine Impurity G | EP | |
| Amlodipine Impurity A | EP | |
| Amlodipine Impurity E | EP | |
| Anisole | Anisole | In-house |
| 3-Bromoanisole | In-house | |
| Aripiprazole | Aripiprazole 1-but-3-enyl-4-(2,3-dichlorophenyl) Piperazine | In-house |
| Aripiprazole 7-but-3-enyloxy-3,4-dihydro-1H-quinolin-2-one | In-house | |
| Aripiprazole Impurity A | EP | |
| Aripiprazole Impurity B | EP | |
| Aripiprazole Impurity G | EP | |
| Aripiprazole imp-1 (N-(2-bromoethyl)-N2-(2,3-dichlorophenyl)ethane-1,2 diamine HBr) | In-house | |
| Aspirin | Aspirin Impurity A | EP |
| Aspirin Impurity B | EP | |
| Aspirin Impurity C | EP | |
| Aspirin Impurity D | EP | |
| Aspirin Impurity E | EP | |
| Aspirin Impurity F | EP | |
| Citalopram | Citalopram Carboxylic acid | In-house |
| Citalopram R-Isomer | In-house | |
| Clarithromycin | Clarithromycin Impurity C | EP |
| Clarithromycin Impurity D | EP | |
| Clarithromycin Impurity E | EP | |
| Clarithromycin Impurity H | EP | |
| Clarithromycin Impurity I | EP | |
| Clarithromycin Impurity J | EP | |
| Clarithromycin Impurity K | EP | |
| Clarithromycin Impurity L | EP | |
| Clarithromycin Impurity M | EP | |
| Clarithromycin Impurity N | EP | |
| Clarithromycin Identity | EPA1SP | |
| Clozapine | Clozapine Impurity A | EP |
| Clozapine Impurity B | EP | |
| Clozapine Impurity C | EP | |
| Clozapine Impurity D | EP | |
| Acetyl Clozapine | In-house | |
| Acetyl Lactame Impurity of Clozapine | In-house | |
| Cysteine | Acetyl Cysteine Impurity A | EP |
| Acetyl Cysteine Impurity B | EP | |
| Acetyl Cysteine Impurity C | EP | |
| Acetyl Cysteine Impurity D | EP | |
| Desloratadine | Desloratadine Impurity C | EP |
| Desloratadine Dihydro Impurity | In-house | |
| Desloratadine Deschloro Impurity | In-house | |
| N-Formyl Desloratadine | EP/USP | |
| Diazepam | Diazepam Impurity A | EP |
| Diazepam Impurity B | EP | |
| Diazepam Impurity C | EP | |
| Diazepam Impurity D | EP | |
| Diazepam Impurity E | EP | |
| Diazepam Impurity F | EP | |
| Diclofenac | Diclofenac Impurity B | EP |
| Diclofenac Impurity C | EP | |
| Diclofenac PEG Ester | In-house | |
| Diclofenac Glyceryl Ester | In-house | |
| Diclofenac Potassium | In-house | |
| Diclofenac Sodium | In-house | |
| Diclofenac Related Compound A | USP | |
| Dicyclomine | Dicyclomine Impurity A | EP |
| Dicyclomine Impurity B | EP | |
| Dicyclomine Keto Impurity ((1-Chlorocyclohexyl)cyclohexyl methanone) | In-house | |
| Digoxin | Digoxin Impurity C | EP |
| Digoxin Impurity G | EP | |
| Digoxin Impurity F | EP | |
| Digoxin Impurity K | EP | |
| Diosmin | Diosmin Impurity A | EP |
| Diosmin Impurity B | EP | |
| Diosmin Impurity C | EP | |
| Diosmin Impurity D | EP | |
| Diosmin Impurity E | EP | |
| Diosmin Impurity F | EP | |
| Diosmetin-7-O-beta-D-glucoside | In-house | |
| Diphenhydramine | Diphenhydramine Impurity B | EP |
| Diphenhydramine Impurity C | EP | |
| Diphenhydramine Related Compound A | USP | |
| Dipyridamole | Dipyridamole Impurity C | EP |
| Dipyridamole Impurity D | EP | |
| N-Alkyl Lisinopril | In-house | |
| Dolutegravir | Dolutegravir Acid Degradative Product A | In-house |
| Dolutegravir Oxidative Degradative Product B | In-house | |
| Ebastine | Ebastine Impurity A | EP |
| Ebastine Impurity B | EP | |
| Ebastine Impurity C | EP | |
| Ebastine Impurity D | EP | |
| Ebastine Impurity E | EP | |
| Ebastine Impurity F | EP | |
| Ebastine Impurity G | EP | |
| Emtricitabine | Emtricitabine Diastereomer | EPAJSP |
| Emtricitabine Impurity J | EP | |
| Emtricitabine Carboxylic Acid | EPA1SP | |
| Emtricitabine Enantiomer | In-house | |
| Emtricitabine S-Oxide | In-house | |
| Enzalutamide | Enzalutamide Impurity A | EP |
| Enzalutamide Impurity B | EP | |
| Enzalutamide Impurity C | EP | |
| Erythromycin | Erythromycin Impurity D | EP |
| Erythromycin Impurity E | EP | |
| Erythromycin Impurity F | EP | |
| Esmolol | Esmolol Acid | In-house |
| Esmolol Isopropylamide Analogue | In-house | |
| N-Ethyl Esmolol | In-house | |
| Eszopiclone | Eszopiclone 2-Amino-5-Chloropyridine | In-house |
| Eszopiclone Desmethyl Impurity | In-house | |
| Eszopiclone N-Oxide Impurity | In-house | |
| Eszopiclone Dibenzoyl-d-tartaric Acid | In-house | |
| Eszopiclone R-Isomer | In-house | |
| Eszopiclone 5-Hydroxy-7-oxo Impurity | In-house | |
| Etodolac | Etodolac Impurity A | EP |
| Etodolac Impurity B | EP | |
| Etodolac Impurity C | EP | |
| Etodolac Impurity D | EP | |
| Etodolac Impurity E | EP | |
| Etodolac Impurity F | EP | |
| Etodolac Impurity G | EP | |
| Etodolac Impurity J | EP | |
| Etodolac Impurity K | EP | |
| Etodolac Impurity L | EP | |
| Etomidate | Etomidate Acid | In-house |
| Etomidate Racemate | In-house | |
| 2-Hydroxypropylmethacrylate Impurity of Etomidate | In-house | |
| 2-Hydroxy-1-methylethylester | In-house | |
| Propylene Glycol Ester of Etomidate | In-house | |
| Etomidate Impurity B | EP | |
| Ezetimibe | Ezetimibe SSS Diastereomer | EP |
| Ezetimibe RRS Diastereomer | EP | |
| Ezetimibe Ketone Impurity | EP | |
| Deschloro Impurity of Ezetimibe | EP | |
| m-Chloroaniline Impurity of Ezetimibe | EP | |
| Famotidine | Famotidine Related Compound A | USP |
| Famotidine Related Compound B | USP | |
| Famotidine Related Compound C | USP | |
| Famotidine Related Compound D | USP | |
| Famotidine Related Compound E | USP | |
| Famotidine Related Compound F | USP | |
| Fenofibrate | Fenofibrate Related Compound 1 (or) Impurity A | USP/EP |
| Fenofibrate Related Compound 2 (or) Impurity B | USP/EP | |
| Fenofibrate Impurity C | EP | |
| Fenofibrate Impurity D | EP | |
| Fenofibrate Impurity E | EP | |
| Fenofibrate Impurity F | EP | |
| Fenofibrate Impurity G (or) Related Compound C | USP/EP | |
| 2-[2-[4-[(4-Chlorophenyl)carbonyl]phenoxy]-2-methylpropanoyl]oxy]-2-methylpropanoic acid | In-house | |
| Fexofenadine | Fexofenadine Related Compound A | USP |
| Fexofenadine Impurity C | EP | |
| Fluconazole | Fluconazole Impurity A | EP |
| Fluconazole Impurity B | EP | |
| Fluconazole Impurity C | EP | |
| Fluconazole Impurity D | EP |